Avelumab, Lorlatanib, Talazoparib, Pemetrexed — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-31 in 3mo
ESTIMATED |
READOUT
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Ave
Phase 3 · Advanced Malignancies, NSCLC |
PFE PFIZER INC | Avelumab, Lorlatanib, Talazoparib, Pemet |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|